MDGL
Madrigal Pharmaceuticals Inc
499.40$
-0.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | 4.3% | 3.5% | 3.3% | 3.3% | 4.3% | 6.3% | 7.6% | 8.6% | 11.0% | 8.5% | |
| – | – | – | 95.7% | 96.5% | 96.7% | 96.7% | 95.7% | 93.7% | 92.4% | 91.4% | 89.0% | 91.5% | |
| – | – | – | 485.7% | 110.6% | 24.8% | 32.2% | 25.4% | 60.6% | 36.2% | 34.9% | 25.0% | 38.2% | |
| – | – | – | 720.4% | 173.0% | 284.4% | 122.3% | 83.2% | 72.8% | 65.1% | 86.2% | 79.4% | 76.0% | |
| – | – | – | 1,206.0% | 283.6% | 161.5% | 154.5% | 117.9% | 133.4% | 111.0% | 121.2% | 104.5% | 116.6% | |
| – | – | – | -1,110.4% | -187.1% | -64.8% | -57.8% | -22.2% | -39.7% | -18.6% | -29.8% | -15.5% | -25.1% | |
| – | – | – | 25.0% | 5.9% | 3.4% | 2.4% | 1.5% | 2.6% | 2.6% | 2.5% | 2.2% | 2.5% | |
| – | – | – | -1,038.2% | -172.0% | -57.5% | -53.4% | -19.9% | -39.8% | -18.2% | -30.3% | -15.9% | -25.3% | |
| – | – | – | – | -0.5% | – | – | – | – | – | – | – | – | |
| – | – | – | -1,038.2% | -172.0% | -57.5% | -53.4% | -19.9% | -39.8% | -18.2% | -30.3% | -15.9% | -25.3% | |
| – | – | – | -1,011.4% | -165.6% | -53.8% | -50.7% | -18.2% | -37.0% | -15.5% | -27.7% | -15.5% | -23.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.